The FDA has issued approval to a new breast cancer drug called Ibrance (palbociclib). The new Pfizer product is specifically for use in post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer and inhibits molecules that enable tumor growth.
The FDA has issued its approval to a new skin care drug called Cosentyx (secukinumab) aimed at treating plaque psoriasis. The condition is an autoimmune disorder that causes itchy, irritated skin and is most common in adults aged 15 to 35. The new drug works by binding to a protein called interleukin (IL)-17A. In doing so, it prevents that protein from reaching its receptor.
Prostate cancer is one of the most dreaded forms of the disease - a major problem in men's health and in the medical community generally. Recent study results released by Medivation Inc. (MDVN) and Astellas Pharma showed that a mid-stage trial of an experimental drug showed some progress. Here a few advancements (and one step back) in the battle to alleviate prostate cancer.